Developer of regenerative medicine products for orthopedic and sports medicine applications.
Carmell Therapeutics Corporation, headquartered in Pittsburgh, Pennsylvania, specializes in pioneering plasma-based bioactive materials (PBM) designed to promote tissue repair and regeneration following injury, illness, and the natural aging process. At the forefront of its product portfolio is CT-101, a leading candidate known for its efficacy in accelerating bone healing. This innovative treatment targets a spectrum of medical applications including tibia fracture repair, foot and ankle fusion, spinal fusion procedures, dental bone graft enhancements, and as a bone void filler. Additionally, Carmell Therapeutics Corporation's advancements extend to tissue healing accelerants, addressing conditions such as androgenetic alopecia and chronic wound management.
Established in 2008, Carmell Therapeutics Corporation has emerged as a key player in the biotechnology sector, committed to transforming healthcare outcomes through cutting-edge bioactive materials. The company's research and development efforts are dedicated to enhancing patient recovery times and outcomes across diverse therapeutic areas. By harnessing the power of plasma-based technologies, Carmell Therapeutics Corporation continues to drive innovation in regenerative medicine, addressing critical medical needs with scientifically backed solutions.
With over a decade of innovation and expertise, Carmell Therapeutics Corporation remains steadfast in its mission to advance the field of biotechnology. Through strategic partnerships and clinical advancements, the company strives to set new standards in tissue repair and regeneration. Based in Pittsburgh, Pennsylvania, Carmell Therapeutics Corporation stands poised to shape the future of healthcare by delivering transformative treatments that improve quality of life and patient care globally.